Publications by authors named "N Frelih"
Article Synopsis
- Some people who have bad reactions to insect stings might have a problem with their mast cells, which can make their reactions worse and affect their treatment.
- A study looked at 1,319 people who needed treatment for bee or wasp stings and found that 21.6% had a specific marker (KIT p.D816V) that showed their mast cells were acting up, especially in those with severe reactions.
- The research also showed that having this marker along with another condition (HαT) made it even more likely for someone to have very bad reactions, highlighting the importance of testing and understanding these conditions for better treatment.
venom-triggered anaphylaxis (HVA) affects up to 8.9% of the general population and is the most frequent cause of anaphylaxis in adults, accounting for approximately 20% of all fatal anaphylaxis cases. Quite often, a fatal reaction is a victim's first manifestation of HVA.
View Article and Find Full Text PDFInfluencing factors on the safety and effectiveness of venom immunotherapy.
J Investig Allergol Clin Immunol
November 2023
Background And Objective: The safety profile of venom immunotherapy (VIT) is a relevant issue and considerable differences in safety and efficacy of VIT have been reported. The primary aim of this study was to evaluate the safety of ACE inhibitors and beta-blockers during VIT, which has already been published. For a second analysis, data concerning premedication and venom preparations in relation to systemic adverse events (AE) during the up-dosing phase and the first year of the maintenance phase were evaluated as well as the outcome of field stings and sting challenges.
View Article and Find Full Text PDFBackground: The relationship between anti-SARS-CoV-2 humoral immune response, pathogenic inflammation, lymphocytes and fatal COVID-19 is poorly understood.
Methods: A longitudinal prospective cohort of hospitalised patients with COVID-19 (n=254) was followed up to 35 days after admission (median, 8 days). We measured early anti-SARS-CoV-2 S1 antibody IgG levels and dynamic (698 samples) of quantitative circulating T-, B- and natural killer lymphocyte subsets and serum interleukin-6 (IL-6) response.
Background: There is controversy whether taking β-blockers or ACE inhibitors (ACEI) is a risk factor for more severe systemic insect sting reactions (SSR) and whether it increases the number or severity of adverse events (AE) during venom immunotherapy (VIT).
Methods: In this open, prospective, observational, multicenter trial, we recruited patients with a history of a SSR and indication for VIT. The primary objective of this study was to evaluate whether patients taking β-blockers or ACEI show more systemic AE during VIT compared to patients without such treatment.